BerGenBio ASA (LON:0RU5)
London
· Delayed Price · Currency is GBP · Price in NOK 1.778
-0.022 (-1.22%)
At close: Apr 29, 2025
BerGenBio ASA Revenue
In the year 2024, BerGenBio ASA had annual revenue of 848.00K NOK with 139.55% growth. BerGenBio ASA had revenue of 681.00K in the quarter ending December 31, 2024, with 92.37% growth.
Revenue
848.00K NOK
Revenue Growth
+139.55%
P/S Ratio
83.31
Revenue / Employee
56.53K NOK
Employees
15
Market Cap
4.97M GBP
Revenue Chart
* This company reports financials in NOK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 848.00K | 494.00K | 139.55% |
| Dec 31, 2023 | 354.00K | -35.00K | -9.00% |
| Dec 31, 2022 | 389.00K | -385.00K | -49.74% |
| Dec 31, 2021 | 774.00K | 173.00K | 28.79% |
| Dec 31, 2020 | 601.00K | -8.30M | -93.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |
BerGenBio ASA News
- 2 months ago - BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ... - GuruFocus